KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Operating Income (2016 - 2025)

Historic Operating Income for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $167.6 million.

  • West Pharmaceutical Services' Operating Income rose 390.58% to $167.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $587.9 million, marking a year-over-year increase of 292.37%. This contributed to the annual value of $569.9 million for FY2024, which is 1569.53% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Operating Income is $167.6 million, which was up 390.58% from $153.7 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Operating Income peaked at $228.4 million during Q2 2022, and registered a low of $107.0 million during Q1 2025.
  • Over the past 5 years, West Pharmaceutical Services' median Operating Income value was $167.6 million (recorded in 2025), while the average stood at $166.3 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Operating Income soared by 10395.75% in 2021, and later tumbled by 3084.93% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Operating Income stood at $184.0 million in 2021, then dropped by 29.51% to $129.7 million in 2022, then rose by 24.06% to $160.9 million in 2023, then decreased by 0.81% to $159.6 million in 2024, then rose by 5.01% to $167.6 million in 2025.
  • Its Operating Income stands at $167.6 million for Q3 2025, versus $153.7 million for Q2 2025 and $107.0 million for Q1 2025.